MacroGenic moves into phase 1 with new leukemia drug
- MacroGenics has initiated phase 1 trials of MDG006 for treatment of relapsed or refractory acute myeloid leukemia
- MGD006 is a humanized dual-affinity re-targeting (DART)(R) bi-specific antibody-based molecule. It binds to both CD123 and CD3.
- This is the first DART candidate to enter clinical study.
Phase 1 study of MGD006 will start with a dose-escalation trial. The lead investigator, John Di Persio, divison chief of Washington University School of Medicine, is focused on exploring this drug's ability to redirect T cells against CD123-positive leukemic blasts in patients with relapsed or refractory AML.
- Pharmaceutical Business Review MacroGenics starts phase 1 trial of MGD006 myeloid leukemia